NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 244)
Posted On: 03/20/2018 5:47:19 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Filing of New Patent Application
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office for the use of its DehydraTECH™ technology to improve the speed and quantity of absorption of active pharmaceutical ingredients through the skin. This update comes on the heels of Lexaria’s recently detailed successful laboratory evaluation of DehydraTECH™ in the transdermal delivery of cannabidiol. Per company data, the platform demonstrated as much as a 225 percent increase in CBD permeability when compared to control formulations featuring leading commercial penetration enhancers, as well as a nearly 1,900 percent increase in CBD permeability when compared to a control formulation that was devoid of any commercial penetration enhancer. This new patent application includes protection for the delivery of all of the active ingredient classes identified in Lexaria’s other issued and pending patent applications, including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office for the use of its DehydraTECH™ technology to improve the speed and quantity of absorption of active pharmaceutical ingredients through the skin. This update comes on the heels of Lexaria’s recently detailed successful laboratory evaluation of DehydraTECH™ in the transdermal delivery of cannabidiol. Per company data, the platform demonstrated as much as a 225 percent increase in CBD permeability when compared to control formulations featuring leading commercial penetration enhancers, as well as a nearly 1,900 percent increase in CBD permeability when compared to a control formulation that was devoid of any commercial penetration enhancer. This new patent application includes protection for the delivery of all of the active ingredient classes identified in Lexaria’s other issued and pending patent applications, including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼